BRIEF-Santhera repositions omigapil in congenital muscular dystrophy

July 17 Thu Jul 17, 2014 1:25am EDT

Related Topics

July 17 (Reuters) - Santhera Pharmaceuticals Holding AG : * Says repositions omigapil in congenital muscular dystrophy * Says initiates clinical development program with public-private partners * Says patient enrolment is expected to start in late 2014 * Source text for Eikon * Further company coverage

FILED UNDER: